Clinical Trial Update: GTX Regimen for Biliary Cancers [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the GTX regimen for biliary tract cancers was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: Columbia University | Conditions: Biliary Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-05-23